1. Home
  2. GTIM vs INAB Comparison

GTIM vs INAB Comparison

Compare GTIM & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Good Times Restaurants Inc.

GTIM

Good Times Restaurants Inc.

HOLD

Current Price

$1.29

Market Cap

13.2M

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.48

Market Cap

14.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GTIM
INAB
Founded
1987
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
14.2M
IPO Year
2013
2020

Fundamental Metrics

Financial Performance
Metric
GTIM
INAB
Price
$1.29
$1.48
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
36.8K
55.9K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$142,315,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$63.60
N/A
Revenue Growth
3.01
N/A
52 Week Low
$1.10
$0.12
52 Week High
$2.09
$4.20

Technical Indicators

Market Signals
Indicator
GTIM
INAB
Relative Strength Index (RSI) 67.02 48.88
Support Level $1.14 $1.35
Resistance Level $1.30 $2.11
Average True Range (ATR) 0.04 0.09
MACD 0.01 0.02
Stochastic Oscillator 71.41 67.86

Price Performance

Historical Comparison
GTIM
INAB

About GTIM Good Times Restaurants Inc.

Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants, which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants, which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers, chicken, frozen custard; slides and drinks.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: